"ZEVASKYN represents a significant milestone for patients with RDEB and for the field of cell-based gene therapy," said Will Geist, Bio-Techne's President, Protein Sciences Segment. "We are honored ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback